Free tool
FAERS Monitor: Vumerity
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211855 or its brand name (Vumerity, Diroximel Fumarate). Reports on generic versions are filed under their own applications.
Reports
12,103
Serious
4,667
39% of reports
Hospitalization
2,344
Death reported
368
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- flushing1,642
- multiple sclerosis1,122
- multiple sclerosis relapse998
- diarrhoea884
- product dose omission issue829
- fatigue795
- nausea760
- headache635
- pruritus603
- memory impairment581
- fall571
- abdominal discomfort532
- product dose omission in error515
- drug ineffective510
- abdominal pain upper477
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 25 |
| 2020 | 479 |
| 2021 | 2,041 |
| 2022 | 2,568 |
| 2023 | 2,539 |
| 2024 | 1,855 |
| 2025 | 1,638 |
| 2026 | 944 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,056 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| multiple sclerosisSignal | 1,122 | 41.7 | 39.4 | 43,621 |
| product dose omission in errorSignal | 515 | 32.2 | 29.5 | 15,262 |
| flushingSignal | 1,642 | 28.5 | 27.2 | 43,069 |
| multiple sclerosis relapseSignal | 998 | 25.7 | 24.2 | 23,363 |
| memory impairmentSignal | 581 | 7.4 | 6.8 | 3,203 |
| abdominal discomfortSignal | 532 | 5.5 | 5.1 | 1,977 |
| product dose omission issueSignal | 829 | 4.9 | 4.6 | 2,607 |
| abdominal pain upperSignal | 477 | 4.0 | 3.7 | 1,093 |
| fallSignal | 571 | 3.0 | 2.8 | 762 |
| pruritusSignal | 603 | 2.7 | 2.5 | 670 |
| diarrhoeaSignal | 884 | 2.4 | 2.2 | 729 |
| fatigue | 795 | 1.8 | 1.7 | 278 |
| headache | 635 | 1.8 | 1.6 | 214 |
| nausea | 760 | 1.7 | 1.6 | 211 |
| drug ineffective | 510 | 0.7 | 0.6 | 86 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.